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Exploring reasons for state-level variation in
incidence of dialysis-requiring acute kidney
injury (AKI-D) in the United States
Zijin Chen1,2*, Charles E. McCulloch3, Neil R. Powe4,5, Michael Heung6,7, Rajiv Saran6,7, Meda E. Pavkov8,
Nilka Rios Burrows8, Raymond K. Hsu2, Chi-yuan Hsu2 and for the Centers for Disease Control and Prevention
Chronic Kidney Disease Surveillance Team Neil Powe

Abstract
Background: There is considerable state-level variation in the incidence of dialysis-requiring acute kidney injury
(AKI-D). However, little is known about reasons for this geographic variation.
Methods: National cross-sectional state-level ecological study based on State Inpatient Databases (SID) and the
Behavioral Risk Factor Surveillance System (BRFSS) in 2011. We analyzed 18 states and six chronic health conditions
(diabetes mellitus [diabetes], hypertension, chronic kidney disease [CKD], arteriosclerotic heart disease [ASHD],
cancer (excluding skin cancer), and chronic obstructive pulmonary disease [COPD]). Associations between each of
the chronic health conditions and AKI-D incidence was assessed using Pearson correlation and multiple regression
adjusting for mean age, the proportion of males, and the proportion of non-Hispanic whites in each state.
Results: The state-level AKI-D incidence ranged from 190 to 1139 per million population. State-level differences in
rates of hospitalization with chronic health conditions (mostly < 3-fold difference in range) were larger than the
state-level differences in prevalence for each chronic health condition (mostly < 2.5-fold difference in range). A
significant correlation was shown between AKI-D incidence and prevalence of diabetes, ASHD, and COPD, as well
as between AKI-D incidence and rate of hospitalization with hypertension. In regression models, after adjusting for
age, sex, and race, AKI-D incidence was associated with prevalence of and rates of hospitalization with five chronic
health conditions--diabetes, hypertension, CKD, ASHD and COPD--and rates of hospitalization with cancer.
Conclusions: Results from this ecological analysis suggest that state-level variation in AKI-D incidence may be
influenced by state-level variations in prevalence of and rates of hospitalization with several chronic health
conditions. For most of the explored chronic conditions, AKI-D correlated stronger with rates of hospitalizations
with the health conditions rather than with their prevalences, suggesting that better disease management
strategies that prevent hospitalizations may translate into lower incidence of AKI-D.
Keywords: Geographic variation, Chronic health condition, AKI-D, Ecological study
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Background
Dialysis-requiring acute kidney injury (AKI-D) is an
important cause of morbidity and mortality in hospitalized patients and is associated with a large public
health burden. We have recently reported considerable geographic variation in incidence of AKI-D in
the United States [1–3] with some states having more
than ten-fold higher incidence than others. However,
little is known about reasons for this geographic
variation.
We hypothesized that geographic variation in prevalence of certain chronic health conditions predisposing
either directly or indirectly to acute kidney injury may
be an important contributor to the observed geographic
variation in AKI-D incidence. Candidate chronic conditions include diabetes mellitus (diabetes), hypertension,
chronic kidney disease (CKD), arteriosclerotic heart disease (ASHD), cancer, and chronic obstructive pulmonary
disease (COPD).
Furthermore, since AKI-D occurs only among hospitalized patients (since acute dialysis cannot be initiated
in the outpatient setting), we hypothesized that geographic variation in the hospitalization rates of patients
with the chronic health conditions is also potentially
important.
To explore these associations, we analyzed data from
18 states derived from two community representative
US databases—the State Inpatient Databases (SID) [4]
and the Behavioral Risk Factor Surveillance System
(BRFSS) [5].
Methods
Study design

We conducted a national, cross-sectional, ecological
study among populations aged 45 years or older in the
United States. We limited our study to adults aged 45
years or older because AKI-D incidence and chronic
health conditions prevalence and hospitalizations are
low in younger populations.
Determining state-level variations in prevalence of
chronic health conditions using BRFSS

Based on the existing literature, we selected a priori
which chronic health conditions to study as candidates
to correlate with AKI-D incidence. We included the top
causes of ESRD (which we presume to be top causes of
CKD also), the top morbid conditions accompanying of
ESRD (as they may act as triggers of acute on chronic
kidney disease), and possible risk factors for AKI-D from
previous study [2, 6, 7]. Specifically, we first determined
the top four primary causes of end-stage renal disease
(ESRD) from the United States Renal Data System
(USRDS): diabetes, hypertension, glomerulonephritis,
and cystic kidney disease [6]. We then determined the
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top ten comorbid conditions reported among ESRD patients from the USRDS: hypertension, diabetes, chronic
heart failure, arteriosclerotic heart disease, other cardiac
disease, peripheral vascular disease, COPD, cerebrovascular accident/transient ischemic attack (CVA/TIA), diabetic retinopathy, and malignant neoplasm [7]. We
finally noted the top ten diagnosis codes related to temporal trends in AKI-D from a prior study: shock, cardiac
arrest and ventricular fibrillation, septicemia, multiple
myeloma,
respiratory
failure,
coagulation
and
hemorrhagic disorders, hypertension, coma stupor and
brain damage, liver disease, and mycoses [2].
State-level prevalence estimates of chronic health conditions were obtained based on self-report data from the
BRFSS in 2011. The BRFSS is the nation’s premier system of health-related telephone surveys that collect data
at the state and local levels from US residents regarding
their health-related risk behaviors, chronic health conditions, and use of preventive services [5, 8]. These data
come from participants in all 50. Starting in 2011, a cell
phone survey and a new methodology to calculate
weighted values were included as components of the
BRFSS [9, 10]. Because the 2011 BRFSS survey did not
capture all the health conditions listed above, we consolidated primary causes of ESRD, the top ten comorbid
conditions among ESRD patients, and the top ten diagnosis codes related to temporal trends of AKI-D into six
chronic health conditions: diabetes, hypertension, CKD,
ASHD, cancer (excluding skin cancer) (henceforth referred to simply as “cancer”), and COPD. The selection
of these six health conditions was made prior to performing any association analyses.
The BRFSS questions and answer choices for these six
chronic health conditions are listed in Supplementary
Table 1 [11]. When the answer for each question was
“yes”, we considered the participant to have this chronic
health condition. When the answer was “no,” we considered the participant to not have this chronic health condition. For ASHD, two relevant questions (concerning
“myocardial infarction” and “angina or coronary heart
disease”) were included and ASHD classification was
based on answering yes to either. Answers given as
“missing,” “refused” or “don’t know/not sure” together
accounted for < 3% of responses for all conditions and
were classified as “no.”
Determining state-level variations in incidence of
hospitalized AKI-D using SID and US census

We used the State Inpatient Databases (SID) to determine the number of AKI-D hospitalizations [3, 4]. We
then used US Census Bureau data to calculate state-bystate incidence of AKI-D.
AKI-D was defined when there was both an acute
renal failure diagnostic code (International Classification
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of Diseases, Ninth Revision, Clinical Modification [ICD9] codes 584.5, 584.6, 584.7, 584.8, or 584.9) and a dialysis procedure code (39.95, V45.11, V45.12, V56.0, or
V56.2) without concurrent arteriovenous fistula creation
or revision procedure codes (39.27, 39.42, 39.43, or
39.93) [1, 3, 12, 13]. Prior studies have showed that this
algorithm produced ≥90% sensitivity, specific, positive
and negative predictive values [1, 3, 12, 13]..
Due to cost reasons, we purchased only 25 out of the
30 SID available in 2011: Arizona (AZ), Arkansas (AR),
California (CA), Colorado (CO), Florida (FL), Iowa (IA),
Kentucky (KY), Massachusetts (MA), Maryland (MD),
Maine (ME), Michigan (MI), Mississippi (MS), North
Carolina (NC), Nebraska (NE), New Jersey (NJ), New
Mexico (NM), New York (NY), Nevada (NE), Oregon
(OR), Rhode Island (RI), South Carolina (SC), Utah
(UT), Vermont (VT), Washington (WA), and West Virginia (WV) (Supplementary Figure 1) [3].
Nineteen SID databased reported > 15 diagnostic
codes. In none of these 19 states did more than a quarter
of the hospitalizations have > 15 diagnostic codes. 19
(non-overlapping) SID databases reported > 6 procedure
codes. In none of these 19 states did more than a tenth
of the hospitalizations have > 6 procedure codes [3]
In our primary analysis, to reduce ascertainment bias,
we did not include SID databases with fewer than 15
diagnostic codes (ME, NE) and we only analyzed the first
15 diagnostic codes listed for each hospitalization (Supplementary Figure 1). We also only analyzed the first 6
procedure codes in our primary analysis (all states had
at least this number of procedure codes) [3].
We counted AKI-D hospitalizations with diagnosis of
ESRD (585.6) on discharge but not on admission. Our
primary analysis did not include states (CO, MS, NC,
UT, WV) in which we could not tell whether ESRD was
an admission diagnosis or a discharge diagnosis [or
both]) (Supplementary Figure 1) [3].
Our primary analysis was therefore based on 18 states
(AZ, AR, CA, FL, IA, KY, MA, MD, MI, NJ, NM, NY,
NV, OR, RI, SC, VT, WA) (Supplementary Figure 1) [3].
We used data from all 25 states in sensitivity analyses.
Here, we only analyzed up to 9 diagnostic codes and up to
6 procedure codes for each state to reduce ascertainment
bias (all states reported at least 9 diagnostic codes and 6
procedure codes) and excluded all hospitalizations containing a diagnostic code for ESRD (585.6) since for five states
(CO, MS, NC, UT, and WV), we could not tell whether a
this diagnosis was already present on admission [3].
Determining state-level variations in rates of
hospitalization with each of the chronic health conditions
from SID, BRFSS, and US census

We identified and compiled hospital discharges related
to each chronic health condition and calculated rates
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using estimated state-level patient populations. We hypothesized that hospitalization rate with each chronic
health condition could be influenced driven by patients
with that chronic health condition who had more severe
disease or had complications that needed to be treated
in the hospital.
Specifically, we used Clinical Classifications Software
(CCS) in SID which collapses the > 14,000 standardized
diagnosis codes in the International Classification of
Diseases-Ninth Revision-Clinical Modification (ICD-9CM) into a smaller number of clinically significant categories [3]. Each one of the six chronic health conditions
of interest were mapped to the following CCS diagnostic
codes: diabetes (CCS diagnostic code 49, 50), hypertension (CCS diagnostic code 98, 99), CKD (CCS diagnostic
code 156, 158), ASHD (CCS diagnostic code 100, 101,
102), cancer (CCS diagnostic code 11–21 and 24–43),
and COPD (CCS diagnostic code 127).
Statistical methods

State-level AKI-D incidences were expressed as per million population (pmp) as described previously [3, 12,
14]. We calculated fold-difference for this by dividing
the highest observed state-level AKI-D incidence by the
lowest observed state-level AKI-D incidence. We classify
states into low/medium/high tiers of AKI-D incidence to
show regional variations on a map of the U.S..
We computed the chronic condition prevalence estimates from the BRFSS and the resident population from
the 2011 US Census Bureau [15]. We calculated rate of
hospitalizations with each chronic health condition per
1000 population as: count of hospitalizations / (chronic
condition prevalence * resident population) * 1000. Folddifferences for these were also calculated taking highest
vs. lowest observed values. (All incident rates are for per
annum.)
To obtain prevalence estimates and associated confidence intervals (CIs), we used complex sample survey
design specifying strata, clusters and sample weights for
the combined landline telephone and cellular telephone
data (“STSTR” was used for strata, “_PSU” for clusters,
and “_LLCPWT” for sampling weights) [16].
Pearson correlation coefficients were used to determine i) the state-level correlation between prevalence of
each chronic health condition and AKI-D incidence, and
ii) the state-level correlation between rate of
hospitalization with each chronic health condition and
AKI-D incidence.
Linear regression analysis was performed to determine
the state-level association between the prevalence of or
rate of hospitalization with each chronic health condition and AKI-D incidence, adjusting for mean age, the
proportion of males, and the proportion of nonHispanic whites in each state. Size of parameter
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estimates and p-values from the linear regression models
were used to gauge which chronic health condition may
have had the greatest influence on AKI-D incidence. We
also compared adjusted R-squared values in different
models for each chronic health condition to evaluate
whether differences in prevalence or rate of
hospitalization with some chronic health conditions
could potentially account for more of the observed
state-level variation in AKI-D incidence.
In all regression models, we checked the linearity assumption. If the relationship between an exposure of
interest and the outcome appeared non-linear, we added
a quadratic term into the model and displayed our results graphically.
As a negative control, we examined skin cancer as a
chronic health condition that we hypothesized would
not have any correlation or association with AKI-D incidence. Information on skin cancer was also based on
self-report in BRFSS (Supplementary Table 1) and we
used CCS diagnostic code 22, 23 in SID.
Data were analyzed using STATA version 14.1 (Stata
Corp., College Station, TX) and verified independently
by a separate analyst using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results
Demographic characteristics of BRFSS respondents
and patients who had AKI-D hospitalizations are
shown in Table 1 (state level breakdown in Supplementary Table 2 and Supplementary Table 3). Individuals with AKI-D hospitalizations were more likely
to be older, male, and non-Hispanic Black than
BRFSS respondents.

Incidence of hospitalized AKI-D

We identified 34,122 hospitalizations with AKI-D in SID
of 18 states. The state-level AKI-D incidence varied considerably (Figure 1), ranging from 190 to 1139 pmp (6.0fold difference) (Supplementary Table 2).

Prevalence of chronic health conditions

The study included 188,997 participants from the BRFSS
among individuals aged 45 years or older in 18 states
(weighted population size = 57,396,000). Estimated
prevalence of the six chronic health conditions of interest varied from state to state (Supplementary Tables 4–
9). For diabetes, the range of state-level prevalence was
11.9 to 18.4% (1.5-fold difference), for hypertension 42.1
to 54.1% (1.3-fold difference), for CKD 2.4 to 5.9% (2.5fold difference), for ASHD 9.3 to 15.8% (1.7-fold difference), for cancer 9.1 to 11.9% (1.3-fold difference), and
for COPD 6.3 to 13.5% (2.1-fold difference).
Rates of hospitalization rates with each of the chronic
health conditions

Compared with state-level variations in disease prevalence, there was greater state-to-state variation in the
rate hospitalization with the chronic health conditions
(e.g., comparing fold-difference from highest to lowest
state). Specifically, rates of hospitalization with diabetes
ranged from 252 to 438 per 1000 patients (1.7-fold difference), whereas that with hypertension ranged from
153 to 278 per 1000 patients (1.8-fold difference), that
with CKD 360 to 1144 per 1000 patients (3.2-fold difference), that with ASHD 289 to 547 per 1000 patients
(1.9-fold difference), that with cancer from 197 to 384
per 1000 patients (1.9-fold difference), and that with
COPD from 213 to 473 per 1000 patients (2.2-fold
difference).
Note the 6-fold range difference in AKI-D incidence
among states (1139/190 pmp) is more than the statelevel variation in chronic health condition prevalence
(mostly < 2.5-fold difference in range) or state-level variation in chronic health condition hospitalization rate
(mostly < 3-fold difference in range).
State-level correlation between prevalence of each
chronic health condition and AKI-D incidence

At the state-level, a significant correlation was shown
between AKI-D incidence and prevalence of diabetes
(r = 0.56; p = 0.01, Fig. 2a), ASHD (r = 0.56; p = 0.01, Fig.

Table 1 Demographic characteristics of AKI-D hospitalizations and the BRFSS population in patients aged 45 years or older for the
18 states in the primary analysis
AKI-D Hospitalizations
(N = 34,122)

BRFSS Population
(weighted N = 57,396,000)

Mean age (SD), yrs

68.2 (12.0)a

61.1 (0.04)

Male, %

57.8

46.9

68.4

69.7

Race
Non-Hispanic White, %

a

Non-Hispanic Black, %

14.3

8.7

Hispanic, %

11.1

12.9

Excluding one state (SC) which only reported age categories
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Fig. 1 Map demonstrating the regional variation of AKI-D incidence in primary analysis with 18 states. The map was drawn using Adobe
Photoshop CS6 version 13.1.2 URL:http://www.adobe.com

2b), and COPD (r = 0.55; p = 0.02, Fig. 2c). No significant
correlation at the state-level was noted between AKI-D
incidence and prevalence of hypertension (r = 0.35; p =
0.15), CKD (r = 0.36; p = 0.14, Fig. 2d) and cancer (r =
0.06; p = 0.82).
State-level correlation between rate of hospitalization
with each chronic health condition and AKI-D incidence

A significant correlation was also shown between AKI-D
incidence and rate of hospitalization with hypertension
(r = 0.51; p = 0.03, Fig. 2e). No significant correlation was
shown for rates of hospitalization with diabetes (r = 0.27;
p = 0.27), CKD (r = 0.03; p = 0.91, Fig. 2f), ASHD (r =
0.17; p = 0.49), cancer (r = 0.23; p = 0.37), and COPD
(r = 0.13; p = 0.60).
Association between the prevalence of and/or rates of
hospitalization rate with each chronic health condition
and AKI-D incidence by linear regression

After controlling for state-level differences in age, sex,
and proportion of non-Hispanic whites, states with
higher prevalence of diabetes, hypertension, ASHD, and
COPD had higher incidence of AKI-D (Table 2). For example, for each 1% higher prevalence of diabetes in the

state, we estimated there was a 70.5 (95% CI: 14.6–
126.3) pmp higher incidence of AKI-D in the state.
We also found that states with higher rates of
hospitalization with any of the selected six chronic
health conditions had higher incidence of AKI-D (with
CKD being borderline/ having the weakest association).
Generally, these relationships were adequately captured
in a linear model. For example, for each 1 per 1000
higher rate of hospitalization with diabetes, we estimated
there was a 3.0 (95% CI: 1.8–4.1) pmp higher incidence
of AKI-D in the state. For cancer, states with higher
hospitalization rates also had higher AKI-D incidence
but the association was not linear and is more accurately
shown graphically in Fig. 3a.
We observed that for most of the chronic conditions,
models with hospitalization rate as the main exposure
had higher adjusted R2 than models with disease prevalence as the main exposure (Table 2). For example, adjusted R2 was 0.350 for diabetes prevalence but adjusted
R2 was 0.780 for diabetes hospitalization rate.
When both prevalence of and rate of hospitalization
with each chronic condition were entered into the linear
regression model, the adjusted R2 values increased even
more (Table 2). The prevalence of five of the six chronic
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Fig. 2 Pearson correlation between AKI-D incidence and selected chronic health conditions for the 18 states in the primary analysis. a AKI-D
incidence and diabetes prevalence. b AKI-D incidence and ASHD prevalence. c AKI-D incidence and COPD prevalence. d AKI-D incidence and
CKD prevalence. e AKI-D incidence and rate of hospitalization with hypertension. f AKI-D incidence and rate of hospitalization with CKD

health conditions (prevalence of cancer remained not
statistically significant) and the rate of hospitalization
with all six diseases were significantly associated with
AKI-D incidence in a positive direction (i.e., higher AKID incidence in states with higher chronic health condition prevalence or hospitalization rate). For cancer

hospitalization rate, the association was again not linear
and more accurately shown graphically in Fig. 3b.
With regard to our negative control, we found that
skin cancer prevalence and hospitalization rate (Supplementary Table 10) were not correlated with AKI-D incidence (Table 2).

Chen et al. BMC Nephrology

(2020) 21:336

Page 7 of 10

Table 2 Linear regression model for AKI-D incidence and each chronic health condition for the 18 states in the primary analysis
Prevalence (%)
Coef. (95% CI)

Hospitalization rate
(per 1000 patients)
P value

Coef. (95% CI)

P value

Adjusted R2

Model 1
Diabetes mellitus

70.5 (14.6126.3)

0.02

–

–

0.350

Hypertension

34.6 (10.5,58.7)

0.01

–

–

0.414

CKD

65.0 (−86.8216.8)

0.37

–

–

0.345

ASHD

70.4 (31.8108.9)

< 0.01

–

–

0.661

Cancer (excluding skin cancer)

−41.4 (− 204.7121.9)

0.59

–

–

0.266

COPD

54.6 (18.1,91.1)

< 0.01

–

–

0.600

Skin Cancer

28.1 (−58.7,11.5)

0.49

–

–

0.324

Model 2
Diabetes mellitus

–

–

3.0 (1.8,4.1)

< 0.01

0.780

Hypertension

–

–

4.5 (2.8,6.1)

< 0.01

0.720

CKD

–

–

0.6 (0.0,1.1)

0.05

0.251

ASHD

–

–

2.3 (1.0,3.6)

< 0.01

0.509

Cancer (excluding skin cancer)

–

–

See Fig. 3a

< 0.01

0.648

COPD

–

–

1.7 (0.3,3.1)

0.02

0.573

Skin Cancer

–

–

4.1 (−16.4,24.6)

0.67

0.305

Model 3
Diabetes mellitus

53.4 (42.7,64.1)

< 0.01

2.9 (2.6,3.3)

< 0.01

0.980

Hypertension

25.6 (17.7,33.5)

< 0.01

3.9 (3.1,4.7)

< 0.01

0.940

CKD

237.7 (143.9331.6)

< 0.01

1.0 (0.6,1.3)

< 0.01

0.823

ASHD

61.7 (41.9,81.4)

< 0.01

1.6 (1.0,2.2)

< 0.01

0.915

Cancer (excluding skin cancer)

23.9 (− 79.8127.6)

0.62

See Fig. 3b

< 0.01

0.625

COPD

55.7 (37.4,74.1)

< 0.01

1.9 (1.2,2.5)

< 0.01

0.916

Skin Cancer

48.1 (36.6132.9)

0.24

9.4 (−10.2,28.9)

0.31

0.296

Model 1: adjusted for mean age, % male, % non-Hispanic White, prevalence of each chronic health condition
Model 2: adjusted for mean age, % male, % non-Hispanic White, hospitalization rate of each chronic health condition
Model 3: adjusted for mean age, % male, % non-Hispanic White, prevalence of each chronic health condition and hospitalization rate of each chronic
health condition
Abbreviations: ASHD Arteriosclerotic heart disease, CKD Chronic kidney disease, COPD Chronic obstructive pulmonary disease

Fig. 3 Rate of hospitalization with cancer and predicted AKI-D incidence for the 18 states in the primary analysis. a Adjusted for age, % male, and
% non-Hispanic White. b Adjusted for age, % male, % non-Hispanic White, and prevalence of cancer
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Sensitivity analysis

In sensitivity analyses using data from 25 states (38,922
AKI-D hospitalizations from the SID (Supplementary
Figure 2) and 200,936 observations [weighted population
size = 67,096,000] from the BRFSS), we observed similar
results in correlation analyses. In regression models, we
get similar results expect for cancer prevalence. Cancer
prevalence was still a significant factor for AKI-D incidence after several adjustments (coefficient = 154.6, 95%
CI 55.6–253.7; p < 0.01) (Supplementary Table 11, Supplementary Figure 3).

Discussion
Epidemiologic studies of kidney disease have focused
mostly on ESRD [17] and CKD [18]. Fewer studies have
focused on AKI and even fewer on geographic variations
in AKI incidence. We recently reported that there is a
large difference between states in the incidence of AKID [3, 14]. The current study is the first attempt, to our
knowledge, to examine factors associated with that
variation.
In this national, cross-sectional, ecological study, we
found that state-level variation in AKI-D incidence is
correlated with state-level variations in prevalence of
and state-level variations in hospitalization rate for several chronic health conditions. These findings suggest
that geographic distribution of diabetes, hypertension,
CKD, ASHD, and COPD (and possibly cancer) may influence geographic distribution of AKI-D.
We acknowledge that firm conclusions cannot be
made by ecological studies and correlation is not causation. But, we believe that it is very plausible state-level
variations in these chronic health conditions are pathophysiologically relevant since these are known to be risk
factors for AKI. For example, diabetes has been recognized as a risk factor for contrast-associated nephropathy and other forms of AKI-D [19, 20]. Hypertension,
common among adults, has been linked to AKI [21, 22].
CKD is closely related to AKI and severity of CKD is associated with progressively higher risk of AKI [23, 24].
AKI is common in ASHD patients who have undergone
coronary artery bypass graft surgery [25] or percutaneous coronary intervention [26]. COPD patients have increased incidence of bacteremia, likely reflecting greater
vulnerability to acquiring severe infections [27, 28], and
this higher prevalence of respiratory tract infectionrelated septicemia could increase the number of AKI-D
episodes. AKI-D can be cancer-related due to intrinsic
renal factors, postrenal factors and chemotherapeutic
agents, which may be intensified in the inpatient setting.
We believe our conclusions are strengthened by the
findings regarding skin cancer, our negative control
(which was also selected a priori). We had hypothesized
that state-level variation in skin cancer prevalence and
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hospitalization rate should not correlate or be associated
with state-level AKI-D since skin-cancer is not a known
AKI risk factor. We indeed observed this. Thus, this provides some reassurance about the specificity of the observed state-level associations between the 6 selected
chronic health conditions and AKI-D.
We believe that a potentially important observation is
that state-level differences in rates of hospitalization with
chronic health conditions (e.g., up to 3.2-fold difference
in range) were larger than the state-level difference in
prevalence for each chronic health condition (e.g., up to
2.5-fold difference in range). Furthermore, as noted, for
most of the chronic conditions, the adjusted R2 was
higher in the models with hospitalization rate as the
main exposure vs. the models with disease prevalence as
the main exposure, which is consistent with the hypothesis that rates of hospitalization with chronic health conditions are more influential than prevalence rates in the
community in explaining state-level variation in AKI-D
incidence. Since it is plausible that patients with poorly
controlled chronic health conditions are the ones more
likely to be admitted, these results highlight the possibility that improved management of chronic health conditions could reduce AKI-D episodes. Our study
potentially identify which states would garner the most
benefit in terms of these prevention strategies. Overall,
intensive patient education programs to improve selfmanagement of chronic conditions and the skill and
supply of non-nephrologists (such as endocrinologists,
cardiologists, pulmonologists, and primary physicians)
may be important modifiable factors to reduce AKI-D
disease burden.
Our study is strengthened by encompassing multiple
states across the nation. To our knowledge, the BRFSS is
the only comprehensive state-level dataset available regarding the chronic health conditions of interest. Previous studies reported that BRFSS data highly agree with
data from other national surveys [29–31]. As a major
improvement of the 2011 BRFSS, the inclusion of survey
data from participants using cellular telephones in
addition to data collected via landline telephones increased representativeness and accuracy [32]. With regard to defining AKI-D incidence, we captured AKI-D
cases using the best-validated set of ICD-9-CM diagnostic and procedure codes [3, 12–14].
However, we recognize a number of limitations. Due
to limitations in the SID data, we did not have data on
all 50 states. Thus our results may not generalize to the
entire country. We lacked clinical data (such as creatinine or blood glucose levels, physician documentation of
medical history or physical examination such as body
mass index, medications prescribed) to capture AKI-D
and chronic health conditions and this may introduce
biases in our estimations of the strengths of associations.
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We identified each health condition using diagnostic
codes and so were not able to capture disease severity.
We were unable to quantify any pre-existing reductions
in glomerular filtration rate for those patients who developed AKI-D. There were other factors which may
contribute to AKI-D incidence (such as state-level variation in economic status, medical and social services,
mix of academic vs. non-academic hospital, number of
intensive care unit bed) which we did not have available
information to adjust for. We were not able to account
for any potential differences in threshold to initiate dialysis or death at home as a competing event that may
vary regionally. Likely because of reliance on patient
self-report, the population prevalence of CKD according
to BRFSS is much lower than the population prevalence
of CKD defined using biochemical markers from the National Health and Nutrition Examination Survey (NHAN
ES) [33, 34]. This misclassification may also explain why
we did not see stronger correlations between AKI-D incidence and CKD prevalence or AKI-D incidence and
rate of hospitalization with CKD in unadjusted analyses,
despite CKD being a very strong AKI risk factor. In
addition, BRFSS does not include those who live in nursing homes or other facilities and relies on respondent
being physically and mentally able to respond to the survey. Thus people with severe comorbidities are underrepresented. The cross-sectional and ecological study design meant we did not have individual level data to make
stronger inferences.

Conclusion
There is considerable state-level variation in the incidence
of dialysis-requiring acute kidney injury (AKI-D). AKI-D
incidence was associated with prevalence of and rates of
hospitalization with five chronic health conditions--diabetes, hypertension, CKD, ASHD and COPD--and rates of
hospitalization with cancer. We believe our results are
provocative and shed light on potential reasons for the
geographic variations in AKI-D incidence. Our results, if
replicated by others, suggest that measures which reduce
hospitalization of patients with chronic health conditions
may translate into lower incidence of AKI-D.
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